Zobrazeno 1 - 10
of 1 895
pro vyhledávání: '"K. Brendel"'
4D perfusion CT of prostate cancer for image-guided radiotherapy planning: A proof of concept study.
Autor:
Lucian Beer, Stephan H Polanec, Pascal A T Baltzer, Georg Schatzl, Dietmar Georg, Christian Schestak, Anja Dutschke, Harald Herrmann, Peter Mazal, Alexander K Brendel, Shahrokh F Shariat, Helmut Ringl, Thomas H Helbich, Paul Apfaltrer
Publikováno v:
PLoS ONE, Vol 14, Iss 12, p e0225673 (2019)
PurposeAdvanced forms of prostate cancer (PCa) radiotherapy with either external beam therapy or brachytherapy delivery techniques aim for a focal boost and thus require accurate lesion localization and lesion segmentation for subsequent treatment pl
Externí odkaz:
https://doaj.org/article/97a6c65301e849c0a264cf1f32cb221e
Autor:
Jean‐François Blain, Angela Y.P. Chen, Morgan A. Brand, James C. Lanter, Christopher J. Holler, Jerusha K. Brendel, Gerhard Koenig, Duane A. Burnett, Raymond S. Hurst
Publikováno v:
Alzheimer's & Dementia. 18
Publikováno v:
Lebensmittelchemie. 76
Autor:
Teresa Macarulla, K. Brendel, Patrick McKay Boland, Kabir Mody, Anna Pedret-Dunn, Tanios Bekaii-Saab, Bin Zhang, Farshid Dayyani, Fiona Maxwell, Zev A. Wainberg, Andrew Dean
Publikováno v:
CPT: pharmacometrics & systems pharmacology, vol 10, iss 12
Scientia
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 12, Pp 1550-1563 (2021)
Scientia
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 12, Pp 1550-1563 (2021)
Pharmacokinetics; Liposomal irinotecan; Safety Farmacocinética; Irinotecán liposomal; Seguridad Farmacocinètica; Irinotecan liposomal; Seguretat Liposomal irinotecan is a liposomal formulation of irinotecan, which prolongs circulation of irinoteca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d425997114a3ce62ba0115186904fe7
https://escholarship.org/uc/item/4f56r0n3
https://escholarship.org/uc/item/4f56r0n3
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Geburtshilfe und Frauenheilkunde. 77:182-191
Autor:
Patricia Rich, V. Gutierrez Calderon, Atilio Navarro, R. Bernabe Caro, Theresa M. Hayes, O. Juan-Vidal, Bin Zhang, Paul A. Bunn, M. Jove Casulleras, Afshin Dowlati, Anna Pedret-Dunn, K. Brendel, Y. Moore, J. Kokhreidze, David R. Spigel, Luis Paz-Ares, Santiago Ponce, Y. Chen
Publikováno v:
Annals of Oncology. 31:S1038-S1039
Autor:
Georg Schatzl, Paul Apfaltrer, Harald Herrmann, Alexander K. Brendel, Helmut Ringl, Peter R. Mazal, Thomas H. Helbich, Stephan H. Polanec, Christian Schestak, Dietmar Georg, Pascal A. T. Baltzer, Anja Dutschke, Shahrokh F. Shariat, Lucian Beer
Publikováno v:
PLoS ONE, Vol 14, Iss 12, p e0225673 (2019)
PLoS ONE
PLoS ONE
PurposeAdvanced forms of prostate cancer (PCa) radiotherapy with either external beam therapy or brachytherapy delivery techniques aim for a focal boost and thus require accurate lesion localization and lesion segmentation for subsequent treatment pl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b23e0b6026aa444d710c23ee961f999
https://www.repository.cam.ac.uk/handle/1810/301657
https://www.repository.cam.ac.uk/handle/1810/301657
Publikováno v:
Annals of Oncology. 30:ix47
Background Cabozantinib, an inhibitor of MET, AXL and VEGF receptors, was recently approved for the treatment of patients with advanced hepatocellular carcinoma (HCC) who had previously received sorafenib, based on findings of the CELESTIAL trial. We
Autor:
Bin Zhang, Teresa Macarulla, K. Brendel, Andrew Dean, Anna Pedret-Dunn, Zev A. Wainberg, Fiona Maxwell, Farshid Dayyani, Christopher A. Lieu, Bruce Belanger, Y. Moore
Publikováno v:
Annals of Oncology. 30:v263
Background Liposomal irinotecan (nal-IRI) is a liposomal formulation of irinotecan which prolongs circulation of irinotecan and its active metabolite SN-38. This analysis describes the population pharmacokinetics (PK) of nal-IRI in patients with vari